Nuvectis Pharma, Inc. is a biopharmaceutical firm that specializes in creating precision medications to address unmet medical needs in the field of oncology. The company has developed two drug candidates: NXP800, an inhibitor that targets the heat shock factor 1 pathway to address cancer; and NXP900, a small molecule drug that inhibits Proto-oncogene c-Src and YES1 kinases. It was founded in 2020 and is located in Fort Lee, New Jersey.